Request Demo

Last update 03 Apr 2026

Telmisartan

Last update 03 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid, Telmisartan

+ [69]

Target

AT1R

Action

antagonists

Mechanism

AT1R antagonists(Angiotensin II Receptor Type 1 antagonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Cardiovascular DiseasesEssential HypertensionHypertension

Inactive Indication

Diabetes MellitusDiabetes Mellitus, Type 2Diabetic Nephropathies+ [6]

Originator Organization

Boehringer Ingelheim GmbH

Active Organization

Boehringer Ingelheim International GmbHNippon Boehringer Ingelheim Co., Ltd.Teva Pharmaceuticals Europe BV

+ [9]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (10 Nov 1998),

Hypertension

RegulationPriority Review (China)

Structure/Sequence

Molecular FormulaC33H30N4O2

InChIKeyRMMXLENWKUUMAY-UHFFFAOYSA-N

CAS Registry144701-48-4

361

Clinical Trials associated with Telmisartan

TCTR20260208008

/ Not yet recruitingPhase 1IIT

A Bioequivalence study of a randomized, open-label, single dose, full replicated crossover design with four-period, two-treatment, and two-sequence of Telmisartan 80 mg tablets relative to MICARDIS 80 MG TABLETS in healthy Thai participants

Start Date02 Jun 2026

Sponsor / Collaborator

Bio-innova Co., Ltd

NCT07370506

/ Not yet recruitingPhase 1/2IIT

Efficacy of Telmisartan in Preventing Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients

This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing therapeutic outcomes, and facilitating the safer administration of anthracycline regimens.

Start Date01 Feb 2026

Sponsor / Collaborator

Tanta University

NCT06815497

/ RecruitingPhase 2IIT

Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care

The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.

Start Date21 Jan 2026

Sponsor / Collaborator

Dartmouth-Hitchcock Medical Center

[+1]

100 Clinical Results associated with Telmisartan

100 Translational Medicine associated with Telmisartan

100 Patents (Medical) associated with Telmisartan

4,004

Literatures (Medical) associated with Telmisartan

01 Jun 2026·Toxicology reports

Telmisartan protects male reproductive function by modulating biochemical, oxidative stress, apoptosis, and DNA integrity in cyclophosphamide-exposed rats

Article

Author: Obaid, Khalid Ali ; Kassid, Ahmed Ageeb ; Philip Rahmani, Maha H ; Mahmood, Ahmed Mohammed

Background:

Cyclophosphamide (CPA) is a common chemotherapy drug known to cause significant damage to testicular health. It induces oxidative stress, inflammation, cell death, and DNA damage. Telmisartan blocks the angiotensin II type 1 receptor and has some activity on PPAR-γ, a receptor involved in cell regulation. It has been shown to have antioxidant and cell-protecting effects in other organs, but its potential to safeguard reproductive health has not been thoroughly investigated.

Objective:

This study aimed to evaluate the protection exerted by telmisartan against CPA-induced testicular injury in rats, addressing its anti-inflammatory and anti-apoptotic mechanisms.

Methods:

56 adult male Sprague-Dawley rats were randomized into seven groups: control, telmisartan control, CPA induction, three telmisartan treatment groups (3, 5, and 7 mg/kg/day), and a melatonin positive control. Treatments have been given for 8 days; CPA (150 mg/kg, i.p.) on the second day. The serum reproductive hormones, sperm quality, oxidative stress factors, apoptotic genes (Bax, Bcl-2, caspase-3), DNA fragmentation, and histopathology were assessed.

Results:

CPA inhibited testosterone, LH, and FSH, decreased sperm quality, increased oxidative stress, proapoptotic markers, and induced DNA fragmentation. Telmisartan improved all of these parameters by administration on a dose-dependent basis, and the treatment with higher doses returned hormone levels, sperm quality, antioxidant defenses and apoptotic balance back to near-normal levels. Telmisartan had similar protective actions to those of melatonin, given at high doses.

Conclusion:

Telmisartan protects from CPA-related testicular toxicity via anti-inflammatory and anti-apoptotic actions.

01 May 2026·JOURNAL OF PHARMACEUTICAL SCIENCES

Cocrystals of telmisartan with ascorbic acid: Enhanced solubility and antiviral potency against Japanese encephalitis virus

Article

Author: Swain, Ranjit Prasad ; Regu, Varaprasad Rao ; Chattopadhyay, Soma ; Vitthal, Tompe Krishna ; Datey, Ankita ; Subudhi, Bharat Bhusan ; Kumar, Shivam

The significant impact of Japanese encephalitis virus (JEV) on society and the lack of any approved antiviral drugs demand urgent attention. Considering the prohibitive cost involved in new antiviral development, repurposing existing drugs is an alternative strategy. Telmisartan (TM) is a prime candidate for repurposing against JEV due to its ability to inhibit JEV infection. Poor aqueous solubility of TM can be a major hurdle in harnessing its repurposing against JEV. Cocrystallization with appropriate coformers has the scope to improve solubility and antiviral properties. Ascorbic acid (Asca), with its proven efficacy as an adjuvant to antivirals, was used as a coformer to develop a cocrystal with TM (1:1) using a novel microwave-assisted synthesis method. From FTIR, NMR, and DSC data, supported by XRD, confirmed the formation of the cocrystal. The ¹H NMR supported the 1:1 stoichiometry. The cocrystal showed adequate stability under refrigeration conditions. Using valid analytical methods, the solubility of the cocrystal was found to be enhanced by 81-fold compared to TM. The significant increase in solubility was also associated with a significant enhancement in ex vivo intestinal permeability of the cocrystal (60%) compared to that of TM (28%). Antiviral assay revealed a 2-fold enhancement in the potency of the cocrystal. This was also associated with a significant increase in selectivity index (29) as compared to TM (14.18), indicating its enhanced antiviral properties. Cocrystallization with Asca enhanced solubility, ex vivo permeability, and antiviral properties of TM, which can encourage its further progress with validation in preclinical and clinical conditions.

01 May 2026·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

A way forward for generic development of telmisartan tablets: Integrating critical material attributes and bio-predictive dissolution for target product profile

Article

Author: Shah, Ravi P ; Pillai, Megha ; Sengupta, Pinaki

This study systematically integrated critical material attributes (CMAs) influencing drug release, focusing on factors such as particle size and excipient composition, and characterization of polymorphic form. As a model compound, a BCS class II drug Telmisartan was selected, and the methodology was evaluated using seven different formulations of Telmisartan through comprehensive analysis. The orthogonal analytical techniques, including chromatography, hot-stage microscopy, NMR spectroscopy, and dissolution testing were employed for evaluating critical quality attributes (CQAs). Systematic efforts were made to develop a biopredictive dissolution method using USP dissolution Apparatus I, II, and IV. Based on the t_max value of telmisartan, a multi-stage dissolution strategy was developed to understand the behaviour of formulation in acidic and neutral pH corresponding to the stomach and duodenum under fasting conditions. After de-formulation experiments, formulations were categorized into different buckets based on the size of API particles (d-90 value of 8 ± 2 µm; 12 ± 2 µm and >15 µm), the type of excipients present (functional excipient and non-functional excipients), and the micro-environmental pH of the formulations. A rank-based approach was applied to evaluate a robust framework for understanding the differences between these generic formulations. This approach not only supports comprehensive formulation development through CMA-CQA correlations, but also aligns with regulatory expectations for adopting multi-dissolution methods as in vitro testing in cases of formulation change requirements with a bio-equivalance waiver for post-approval formulation changes.

News (Medical) associated with Telmisartan

16 Mar 2026

·www.biospace.com

George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement

Arrotex gains exclusive rights in Australia and New Zealand to innovative single pill combination of three hypertension medicines, including two doses that are lower than those currently available in single pill combinations GMRx2 is designed to deliver blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, with an established safety profile George Medicines receives upfront licensing fee and is eligible for commercial milestone payments, as well as a future recurring revenue stream through a tiered royalty rate on sales in Australia and New Zealand Arrotex to seek regulatory approval of GMRx2 in Australia and New Zealand London, UK, 16 March 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Arrotex Pharmaceuticals (“Arrotex”), a leading Australian pharmaceutical company and Australia’s largest supplier of medicines by prescription volume, granting Arrotex exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Australia. GMRx2 is an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the treatment of hypertension, developed in three doses, including two doses that are lower than those currently available in single pill combinations. By leveraging a multi-mechanism approach and lower doses, GMRx2 is formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the known safety profiles of existing antihypertensive medicines. Under the terms of its licensing agreement, George Medicines will receive an upfront licensing fee and is eligible for commercial milestone payments, as well as a future recurring revenue stream through a tiered royalty rate on sales of GMRx2 in the licensed territory. In return, Arrotex is granted a license to exclusively commercialize GMRx2, supplied by George Medicines. Arrotex is responsible for seeking regulatory approval of GMRx2, supported by George Medicines, with upcoming applications to Australia’s Therapeutic Goods Administration and the New Zealand Medicines and Medical Devices Safety Authority. Mark Mallon, Chief Executive Officer of George Medicines, said: “This latest partnership in our global commercialization strategy for GMRx2 signals our commitment to extend the reach of this triple combination product to all corners of the globe. The George Institute for Global Health, which founded George Medicines, was established in Australia and so it is a significant moment for us to bring GMRx2 one step closer to people living with hypertension in the Institute’s home country. As Australia's largest pharmaceutical provider, and with its significant commercial capabilities, Arrotex is an ideal partner to support us in delivering on the potential of GMRx2 to help address key challenges in current hypertension treatment approaches.” Monique Jonson, General Manager, Innovation, at Arrotex Pharmaceuticals, said: “Our partnership with George Medicines reflects Arrotex’s ongoing commitment to bringing innovative, life-changing therapies to Australia and New Zealand. Through our unprecedented operational and commercial capabilities, we are well placed to facilitate access for patients and look forward to working with the George Medicines team on our upcoming regulatory submissions for GMRx2.” Around one in three adults in Australia (6.8 million) are living with high blood pressure with only half of those aware of their condition and receiving treatment. More than a million of those diagnosed and treated do not have their blood pressure effectively controlled 1 . In New Zealand, the prevalence of hypertension in adults is 31% (968,000), and only around a quarter have the condition effectively controlled 2 . Most patients with hypertension will require two or more medicines to bring their blood pressure under control, and globally recognized treatment guidelines acknowledge the preferred use of single pill combination therapy and the benefit of their early use. 3,4,5 To date, George Medicines has granted licensing and supply agreements for GMRx2 in Brazil, Cananda, Mexico, Colombia and Central America, and the United States, with further collaborations anticipated as part of the Company’s commitment to bring the value of this important medicine to patients globally. George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes with a focus on addressing global health inequity. The Company is backed by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia’s leading life sciences venture capital firm. Ends National Hypertension Taskforce Australia 2 WHO Hypertension New Zealand 2023 country profile 3 European Heart Journal, Volume 45, Issue 38, 7 October 2024, Pages 3912–4018, 4 Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health Organization ; 2021 5 CMAJ May 26, 2025 197 (20) E549-E564; About GMRx2 GMRx2 is a combination tablet of telmisartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker and indapamide, a thiazide-like diuretic, available in three dosage forms – 10/1.25/0.625 mg; 20/2.5/1.25 mg and 40/5/2.5 mg. Its development is backed by a comprehensive clinical program, including two pivotal Phase III studies, published in 2024 in the Journal of the American College of Cardiology and The Lancet . In these trials the triple combination demonstrated significantly reduced blood pressure (BP) and improved BP control rates, when compared against dual therapy and against placebo. In both trials, tolerability was good, with no increase in withdrawal from treatment due to adverse events. GMRx2 was investigated in the Nigerian VERONICA trial , which compared the triple combination with standard of care and reported better BP lowering among those receiving GMRx2, with good tolerability compared to the standard of care protocol. A global trial led by The George Institute for Global Health and funded by the National Health and Medical Research Council (NHMRC) Australia and the Brazilian Ministry of Health, investigating the potential of GMRx2 to significantly reduce the risk of recurrent stroke in people who have had intracerebral hemorrhage (the most severe type of stroke) completed in 2025. The study met the primary endpoint, with GMRx2 demonstrating a statistically significant and clinically meaningful reduction of recurrent stroke compared to matching placebo. About George Medicines George Medicines is a late-stage biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic diseases with innovative single-pill combinations of existing treatments, designed for a balance of efficacy and safety, with the potential to improve patient adherence. Multi-mechanism, single-pill combinations offer the potential to bring significant improvements in clinical outcomes with cardiometabolic disorders, including hypertension, which remain among the leading causes of premature death and disability worldwide. For more information, please visit . About Arrotex Pharmaceuticals Arrotex Pharmaceuticals is the largest and most diversified pharmaceutical company in Australia, offering the most extensive range of prescription products across the spectrum of therapeutic areas. Proudly Australian-owned and part of DBG Health, Arrotex has over 15 years of proven success in representing branded medicines and has become the Australian partner of choice for pharmaceutical companies seeking to grow and protect their brands while enhancing patient access to medicines for Australians. Safe Harbor Statement This press release contains “forward-looking statements,” including statements relating to George Medicines’ financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential. In addition, this press release also contains forward-looking statements relating to George Medicines’ growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including George Medicines’ ability to successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of drug candidates. Media contacts ICR Healthcare David Daley, Lindsey Neville, Tom Daniel georgemedicines@icrhealthcare.com ; Tel: +44 (0) 203 709 5700

Clinical ResultLicense out/inPhase 3

11 Mar 2026

·www.biospace.com

George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea

George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, supported by an established safety profile George Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, as well as a future recurring revenue stream through stepped royalties on sales in Korea Fifth major licensing and supply agreement for GMRx2 as George Medicines expands commercialization strategy to advance cardiovascular care London, UK, 11 March 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Ahngook Pharmaceutical Co. Ltd (“Ahngook Pharm”) (KOSDAQ: 001540), of Seoul, Korea, granting Ahngook Pharm exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Korea. GMRx2 is an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the treatment of hypertension in adults, developed in three doses, including two doses that are lower than those currently available in single pill combinations. Its multi-mechanism approach and available doses are formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the safety pro established antihypertensive medications. Under the terms of the licensing agreement, George Medicines will receive an upfront licensing fee from Ahngook Pharm and is eligible for regulatory and commercial milestone payments, as well as a future recurring revenue stream through a stepped royalty rate on sales of GMRx2 in the licensed territory. In return, Ahngook Pharm is granted a license to exclusively commercialize GMRx2, supplied by George Medicines. Ahngook Pharm is responsible for seeking regulatory approval of GMRx2, with support from George Medicines. Mark Mallon, Chief Executive Officer of George Medicines, said: “In Ahngook Pharmaceutical we have a strong commercial partner who shares our belief in the potential of GMRx2 to help address key challenges in current hypertension treatment approaches. Through our partnership we have an opportunity to advance cardiovascular care, and we look forward to working with the team to support GMRx2’s regulatory approval in Korea.” Park In-choul, Chief Executive Officer of Ahngook Pharmaceutical, said: “This agreement expands our cardiovascular portfolio and signals our continued commitment to improve outcomes for patients. We look forward to working with George Medicines to bring this important treatment option to patients in Korea.” George Medicines continues to build its global commercialization strategy for GMRx2, with this latest collaboration following licensing and supply agreements with Azurity Pharmaceuticals in the US, Bausch Health in Canada, Mexico, Colombia and Central America, Biolab Farmacêutica in Brazil, and Orient EuroPharma in Southeast Asia. These partnerships demonstrate George Medicines’ commitment to bringing the proven clinical efficacy and established safety pro GMRx2 to patients worldwide. George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes with a focus on addressing global health inequity. The Company is backed by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia’s leading life sciences venture capital firm. Ends About GMRx2 GMRx2 is a combination tablet of telmisartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker and indapamide, a thiazide-like diuretic, available in three dosage forms – 10/1.25/0.625 mg; 20/2.5/1.25 mg and 40/5/2.5 mg. Its development is backed by a comprehensive clinical program, including two pivotal Phase III studies, published in 2024 in the Journal of the American College of Cardiology and The Lancet . In these trials the triple combination demonstrated significantly reduced blood pressure (BP) and improved BP control rates, when compared against dual therapy and against placebo. In both trials, tolerability was good, with no increase in withdrawal from treatment due to adverse events. GMRx2 was investigated in the Nigerian VERONICA trial , which compared the triple combination with standard of care and reported better BP lowering among those receiving GMRx2, with good tolerability compared to the standard of care protocol. A global trial investigating the potential of GMRx2 for the prevention of stroke in people who have had intracerebral hemorrhage (the most severe type of stroke) is ongoing. About George Medicines George Medicines is a late-stage biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic diseases with innovative single-pill combinations of existing treatments, designed for a balance of efficacy and safety, with the potential to improve patient adherence. Multi-mechanism, single-pill combinations offer the potential to bring significant improvements in clinical outcomes with cardiometabolic disorders, including hypertension, which remain among the leading causes of premature death and disability worldwide. For more information, please visit . Safe Harbor Statement This press release contains “forward-looking statements,” including statements relating to George Medicines’ financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential. In addition, this press release also contains forward-looking statements relating to George Medicines’ growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including George Medicines’ ability to successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of drug candidates. Media contacts ICR Healthcare David Daley, Lindsey Neville, Tom Daniel georgemedicines@icrhealthcare.com ; Tel: +44 (0) 203 709 5700

License out/inPhase 3AHA

25 Feb 2026

·www.biospace.com

George Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient EuroPharma in Southeast Asia

GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, supported by an established safety profile George Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, along with a future recurring revenue stream through stepped royalties in Southeast Asia Fourth licensing and supply agreement for GMRx2 reflects continued global partner interest, with further partnerships anticipated as George Medicines advances its strategy to expand global patient access London, UK, 25 February 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Orient EuroPharma (“OEP”) (TWO: 4120), a leading multinational pharmaceutical company headquartered in Taiwan, granting OEP exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Southeast Asia. GMRx2 is an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the treatment of hypertension, developed in three doses, including two doses that are lower than those currently available in single pill combinations. Its multi-mechanism approach and available doses are formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the safety pro established antihypertensive medications. Under the terms of the licensing agreement, George Medicines will receive an upfront licensing fee and is eligible for regulatory and commercial milestone payments, as well as a future recurring revenue stream through a stepped royalty rate on sales of GMRx2 in the licensed territory. In return, OEP is granted a license to exclusively commercialize GMRx2, supplied by George Medicines. OEP is responsible for seeking regulatory approval of GMRx2, with support from George Medicines. Mark Mallon, Chief Executive Officer of George Medicines, said: “ This exclusive licensing and supply agreement with Orient EuroPharma marks another important step in the global expansion of GMRx2, adding Southeast Asia to our growing network of partners across the US, Canada, Mexico, Colombia, Central America and Brazil. Hypertension remains a major and growing health challenge across Southeast Asia, with high prevalence, and low control rates. GMRx2’s proven clinical efficacy, multiple dosing options, and established safety pro it well to address unmet need in hypertension management and we look forward to working with Orient EuroPharma to expand access to this important therapy across the region.” Calvin Tsai, Chief Executive Officer of Orient EuroPharma, said: “We are pleased to partner with George Medicines as part of the continued global expansion of GMRx2. This agreement reflects our shared commitment to improving cardiovascular outcomes and brings an innovative triple combination therapy to Southeast Asia. With our established regional presence and expertise in regulatory and commercial execution, we are well positioned to support the development and launch of GMRx2 and to help broaden patient access across Southeast Asia.” This agreement further strengthens George Medicines’ global commercialization strategy for GMRx2, following licensing and supply agreements with Azurity Pharmaceuticals in the US, Bausch Health in Canada, Mexico, Colombia and Central America, and Biolab Farmacêutica in Brazil. Together, these partnerships demonstrate growing global interest in GMRx2 and its potential to address unmet needs in hypertension treatment. Additional partnerships are anticipated as part of George Medicines’ commitment to bringing the benefits of GMRx2 to patients worldwide. George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes with a focus on addressing global health inequity. The Company is backed by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia’s leading life sciences venture capital firm. Ends About GMRx2 GMRx2 is a combination tablet of telmisartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker and indapamide, a thiazide-like diuretic, available in three dosage forms – 10/1.25/0.625 mg; 20/2.5/1.25 mg and 40/5/2.5 mg. Its development is backed by a comprehensive clinical program, including two pivotal Phase III studies, published in 2024 in the Journal of the American College of Cardiology and The Lancet . In these trials the triple combination demonstrated significantly reduced blood pressure (BP) and improved BP control rates, when compared against dual therapy and against placebo. In both trials, tolerability was good, with no increase in withdrawal from treatment due to adverse events. GMRx2 was investigated in the Nigerian VERONICA trial , which compared the triple combination with standard of care and reported better BP lowering among those receiving GMRx2, with good tolerability compared to the standard of care protocol. A global trial investigating the potential of GMRx2 for the prevention of stroke in people who have had intracerebral hemorrhage (the most severe type of stroke) is ongoing. About George Medicines George Medicines is a late-stage biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic diseases with innovative single-pill combinations of existing treatments, designed for a balance of efficacy and safety, with the potential to improve patient adherence. Multi-mechanism, single-pill combinations offer the potential to bring significant improvements in clinical outcomes with cardiometabolic disorders, including hypertension, which remain among the leading causes of premature death and disability worldwide. For more information, please visit . About Orient EuroPharma Co., Ltd. Orient EuroPharma Co., Ltd. (OEP), established in 1982, has grown into a leading multinational pharmaceutical company headquartered in Taiwan. Listed on the Taipei Exchange (TPEx) since 2003. (4120.TW), OEP has built a strong presence across Southeast Asia, with extensive sales network in the region. OEP’s diversified portfolio spans prescription pharmaceuticals, oncology treatments, cosmeceuticals, and infant-to-adult nutrition and health products. The company also operates a dedicated subsidiary for innovative drug development and manufacturing. With integrated capabilities in pharmaceutical R&D, clinical trials, manufacturing, and regional marketing, OEP continues to advance healthcare solutions throughout Taiwan and the broader Asia-Pacific region. Safe Harbor Statement This press release contains “forward-looking statements,” including statements relating to George Medicines’ financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential. In addition, this press release also contains forward-looking statements relating to George Medicines’ growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including George Medicines’ ability to successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of drug candidates. Media contacts ICR Healthcare David Daley, Lindsey Neville, Tom Daniel georgemedicines@icrhealthcare.com ; Tel: +44 (0) 203 709 5700

License out/inPhase 3AHA

100 Deals associated with Telmisartan

External Link

KEGG	Wiki	ATC	Drug Bank
D00627	Telmisartan	C09CA07	DB00966

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	European Union	Actavis Group PTC ehf	29 Sep 2010
Cardiovascular Diseases	Iceland	Actavis Group PTC ehf	29 Sep 2010
Cardiovascular Diseases	Liechtenstein	Actavis Group PTC ehf	29 Sep 2010
Cardiovascular Diseases	Norway	Actavis Group PTC ehf	29 Sep 2010
Essential Hypertension	European Union	Bayer AG	11 Dec 1998
Essential Hypertension	Iceland	Bayer AG	11 Dec 1998
Essential Hypertension	Liechtenstein	Bayer AG	11 Dec 1998
Essential Hypertension	Norway	Bayer AG	11 Dec 1998
Hypertension	United States	Boehringer Ingelheim GmbH	10 Nov 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertriglyceridemia	Phase 3	Germany	Bayer AG	01 Nov 2007
Metabolic Syndrome	Phase 3	Germany	Bayer AG	01 Nov 2007
Hypercholesterolemia	Phase 3	Czechia	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	France	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Germany	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Hong Kong	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Netherlands	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Russia	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Slovakia	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	South Africa	Boehringer Ingelheim GmbH	01 Apr 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02373163 (INTERVENCION Trial \| INTERVENCION, CTgov)	Phase 4	Hypertension	166	Hydrochlorothiazide (Diuretic)	mjzcjnwsvl(ycvisksxqi) = efxwuficag swdcackikd (vprodeqhuh, 8.4) View more	-	29 Jul 2025
				Amlodipine (Calcium-channel Blocker)	mjzcjnwsvl(ycvisksxqi) = ptcworzlyc swdcackikd (vprodeqhuh, 9.2) View more
ESH2025	Phase 4	Essential Hypertension	88	Metoprolol 25 mg/50 mg + Telmisartan 40 mg	ktsiczpobj(ckltenwugf) = yjzvxwkjtx udkwanxrpr (gehaifxfob ) View more	Positive	23 May 2025
AD-209 (ESH2025)	Phase 2	Hypertension	221	AD-209; telmisartan 20 mg/amlodipine 2.5 mg/chlorthalidone 6.25 mg	tuzsmijqyf(hlmobzeryh) = frbkukbrct pvhegtizmt (aonbrpvpjc ) View more	Positive	23 May 2025
				AD-209-1A; telmisartan 20 mg/amlodipine 2.5 mg	ontpknmxwl(lnclzttocu) = qkjrnbdjsa toyediplnx (qtzmucecao )
ESH2025	Not Applicable	Hypertension	834	Telmisartan 20 mg + Amlodipine 2.5 mg	njcothpdkf(zdmnecbotz) = nfmcfyllcx bijornydsm (cgganurrjw ) View more	Positive	23 May 2025
				Telmisartan 20 mg + Indapamide 1.25 mg	njcothpdkf(zdmnecbotz) = qotiiieoxl bijornydsm (cgganurrjw ) View more
NCT04518293 (GMRx2, Pubmed \| Lancet)	Phase 3	Hypertension	1,385	GMRx2 (telmisartan 20 mg, amlodipine 2·5 mg, and indapamide 1·25 mg)	qehmvypsrc(xnwftayqhx) = souhjuraim xlevqtpmds (rvyjlfuzjc )	Positive	01 Oct 2024
NCT02471833 (HEART, CTgov)	Phase 1/2	Alzheimer Disease	61	Telmisartan 20mg (Telmisartan 20mg)	zypwaemvae(ldpitgoojl) = htdlyzquja thgkifponw (wjjnrlzssk, 1425.34) View more	-	23 May 2024
				Telmisartan 40mg (Telmisartan 40mg)	zypwaemvae(ldpitgoojl) = vvuvixxxlr thgkifponw (wjjnrlzssk, 1509.02) View more
NCT02338232 (CTgov)	Not Applicable	Acute Graft Versus Host Disease	32	Telmisartan	undgebbiag = prmlgmjyyx qvboiuzcvl (dwqqlvuamk, vrihvkoqbc - axeomcnvcc) View more	-	01 May 2024
NCT04360551 (CTgov)	Phase 2	COVID-19 \| Complication	24	Telmisartan 40mg (Telmisartan)	rzfjciktzn(ufkmtpxzel) = osqpxlxvfu itatbfodix (dluqpsbcop, ccguxasmcd - uhotctoumx) View more	-	21 Aug 2023
				Placebo (Placebo)	rzfjciktzn(ufkmtpxzel) = ptrdpzwnvf itatbfodix (dluqpsbcop, vcsfcvlpid - locisccwso) View more
NCT04736329 (TRIUMF trial, Pubmed \| Egypt Heart J)	Not Applicable	Heart failure with reduced ejection fraction	107	Telmisartan	vvrubhedzg(lrllljxlyy) = vjbmhwkdtf rwryhyrcdh (qektgqipfv ) View more	Positive	08 Aug 2023
				Enalapril	vvrubhedzg(lrllljxlyy) = vgaqqxfnqz rwryhyrcdh (qektgqipfv ) View more
NCT04736329 (TRIUMF trial, ESC2023)	Not Applicable	Heart failure with reduced ejection fraction	107	Telmisartan	zzlqruxrhl(pchgyaemcs) = hsatbfzubk thpqqyjhoa (qwpmrywkfk ) View more	-	20 May 2023
				Enalapril	zzlqruxrhl(pchgyaemcs) = jrlcllwrrl thpqqyjhoa (qwpmrywkfk ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis